Provention Bio, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Provention Bio, Inc.
Keeping Track: Provention Teplizumab, AZ Anifrolumab Headline Submissions; AZ Brilinta Gains Stroke Risk Reduction Claim
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Keeping Track Of Submissions: Myovant’s First Relugolix NDA; Merck Resubmits Longer Keytruda Dosing; Biogen Adjusts Aducanumab Rolling Target
The latest news and highlights about submissions for US approval, from the Pink Sheet FDA Performance Tracker.
Biopharma companies struggle with which trials, if any, to pause or delay. Lilly said it wants to ease the burden on health care facilities, while Galapagos said its choice is related to patient safety.
Clinical trials across the board are being impacted by coronavirus and Syncona, the investment powerhouse behind a number of UK cell and gene therapy biotechs, says that its portfolio companies are facing considerable delays.
- Specialty Pharmaceuticals
- Large Molecule